<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Co-occurring substance use disorder and anxiety-related disorders in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Co-occurring substance use disorder and anxiety-related disorders in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Co-occurring substance use disorder and anxiety-related disorders in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sudie E Back, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H20550097"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Substance use disorder (SUD) commonly co-occurs in anxiety disorders, trauma- and stressor-related disorders, and obsessive compulsive and related disorders [<a href="#rid1">1-5</a>]. The association between these disorders is multifaceted. Anxiety-related disorders may increase the risk for the development of SUDs and may alter the presentation and treatment outcome of SUDs. SUDs may alter the presentation and outcome of treatment for anxiety-related disorders.</p><p>The complexity of these comorbidities highlights the importance of a comprehensive understanding of the symptoms of each disorder, proper diagnosis, and use of effective treatments as well as consideration of potentially toxic drug-drug interactions, medication abuse liability, and patient adherence.</p><p>This topic reviews the epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of co-occurring SUD and anxiety-related disorders. The treatment of co-occurring SUD and anxiety-related disorders is described separately. Individual anxiety-related disorders and SUDs are described separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14344.html" rel="external">"Treatment of co-occurring anxiety-related disorders and substance use disorders in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15915.html" rel="external">"Agoraphobia in adults: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">"Benzodiazepine use disorder"</a>.)</p><p></p><p class="headingAnchor" id="H20550104"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Substance use disorders (SUDs) have been found to co-occur at an increased rate in individuals with posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder (SAD) compared to rates in the general population. There are mixed findings regarding the co-occurrence of obsessive-compulsive disorder (OCD) and SUDs.</p><p class="headingAnchor" id="H554290"><span class="h2">Substance use disorders</span><span class="headingEndMark"> — </span>The National Epidemiologic Survey on Alcohol and Related Conditions-III assessed 36,309 adults from 2012 to 2013 in the general population using the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Findings show that lifetime and past 12-month prevalence rates for alcohol use disorder, the most common SUD, were 29.1 and 13.9 percent respectively [<a href="#rid6">6</a>]. For drug use disorder, lifetime, and past 12-month prevalence rates were 9.9 and 3.9 percent, respectively [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H17734023"><span class="h2">Posttraumatic stress disorder</span><span class="headingEndMark"> — </span>PTSD, which has an estimated lifetime prevalence of 6.4 to 7.8 percent [<a href="#rid8">8</a>] in United States general population, has been shown to commonly co-occur with SUDs [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The lifetime prevalence of SUDs in persons with non-military PTSD has been reported to range from 21.6 to 43 percent, compared with a range of 8.1 to 24.7 percent in individuals without PTSD [<a href="#rid1">1,9,12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 2633 individuals in the general United States adult population found that cocaine and opiate users had the highest rates of trauma exposure and PTSD [<a href="#rid14">14</a>]. Similarly, in a 2017 study of 4025 individuals exposed to prescription opioids from the National Epidemiologic Survey on Alcohol and Related Conditions-III, individuals with a baseline PTSD diagnosis were at increased risk of developing an opioid use disorder [<a href="#rid15">15</a>]. Among 170 patients seeking treatment for opioid dependence and chronic pain, 20.6 percent had current PTSD [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 11,103 adults who endorsed lifetime trauma exposure and alcohol use, bidirectional temporal associations between PTSD and alcohol use disorder were found, indicating that individuals with one of these disorders had increased likelihood of developing the other [<a href="#rid16">16</a>].</p><p></p><p>Compared with the general population, military personnel are at increased risk of both PTSD and SUDs [<a href="#rid17">17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A study of over 88,000 United States veterans returning from the Iraq war found that 16.7 percent had symptoms of PTSD at six months post-deployment [<a href="#rid18">18</a>]. A study of 1822 United States infantry soldiers found that 12 percent screened positive for a diagnosis of PTSD using DSM-5 criteria; in 177 soldiers exposed to combat, 18 percent were positive for PTSD [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Millennium Cohort Study, which included over 48,000 military personnel, 53.6 percent reported binge drinking and 15.2 percent reported alcohol related problems [<a href="#rid20">20</a>]. Deployment and exposure to combat were related to increased risk of binge drinking (odds ratio 1.46) and alcohol-related problems (odds ratio 1.63).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 1120 United States soldiers found that 25 percent screened positive for alcohol misuse three to four months postdeployment [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a sample of 3157 United States veterans aged 21 and older from the National Health and Resilience Veterans Study, 16.4 percent were positive for probable current PTSD and 14.8 percent were positive for probable current alcohol use disorder. Among those with probable PTSD, 16.8 percent were also positive for probable alcohol use disorder. Among those with probable alcohol use disorder, 20.3 percent were also positive for probable PTSD [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H17734030"><span class="h2">Generalized anxiety disorder</span><span class="headingEndMark"> — </span>GAD has a lifetime prevalence in the general population of 5.7 percent [<a href="#rid23">23,24</a>]. The likelihood of having GAD has been strongly associated with the presence of alcohol or drug use disorders in data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), which is based on a nationally representative sample in the United States [<a href="#rid7">7,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p>Across several studies, the prevalence of GAD among patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) alcohol use disorder ranged from 8.3 to 52.6 percent [<a href="#rid26">26</a>]. Data from the National Comorbidity Study (NCS), a nationally representative sample of United States adults, found an association between lifetime GAD and lifetime use of stimulants (odds ratio 2.07), cocaine (odds ratio 2.39), hallucinogens (odds ratio 5.09), and heroin (odds ratio 4.27) [<a href="#rid27">27</a>]. Data from one study of treatment-seeking individuals with DSM-IV opioid dependence found that 15.9 percent had current GAD [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H17734037"><span class="h2">Panic disorder</span><span class="headingEndMark"> — </span>Data from the Epidemiological Catchment Area study in five United States cities found a lifetime prevalence of panic disorder among adults of 1.5 percent [<a href="#rid28">28</a>]. Thirty-six percent of patients with panic disorder were additionally diagnosed with an SUD. In a cross-national epidemiologic study of DSM-5 panic disorder and panic attacks in 25 different countries, lifetime prevalence of panic disorder was 1.7 percent, and lifetime prevalence of panic attacks was 13.2 percent. The majority (80.4 percent) of those with lifetime panic disorder had at least one comorbid mental health disorder. Among those with panic disorder, 26.2 percent had a comorbid SUD [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Data from four large epidemiological surveys found that the estimated lifetime risk of panic disorder in individuals with DSM-IV diagnoses of alcohol abuse or dependence ranged from 0.97 to 3.82 percent, compared to individuals without an SUD [<a href="#rid28">28,30-33</a>]. A study of 1071 subjects participating in the National Household Survey on Drug Abuse in the United States estimated that cocaine use was associated with a 3.3-fold excess occurrence of panic attacks [<a href="#rid34">34</a>]. The lifetime prevalence of panic disorder with and without agoraphobia among patients with an opiate use disorder was 5 percent and 14 percent, respectively [<a href="#rid35">35</a>]. A prospective study of 2548 young adults found that panic disorder was a significant predictor of hazardous alcohol use and the persistence of alcohol use disorder [<a href="#rid36">36</a>]. The presence of a lifetime diagnosis of drug use disorder was associated with panic disorder [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H17734046"><span class="h2">Social anxiety disorder</span><span class="headingEndMark"> — </span>Two studies of nationally representative samples in the United States estimated the lifetime prevalence of SAD to range from 5.0 to 13.3 percent and the 12-month prevalence to range from 2.8 to 7.9 percent [<a href="#rid1">1,37</a>]. Alcohol use disorders in individuals with SAD were common, for example, the NESARC found a 48 percent lifetime prevalence [<a href="#rid37">37</a>]. A study demonstrated modestly increased associations between lifetime SAD and lifetime stimulant, cocaine, hallucinogen, and heroin use (odds ratios 1.86, 1.45, 2.3, and 1.6 respectively) [<a href="#rid27">27</a>]. A strong association has been observed between SAD and marijuana use. The NCS found that individuals with SAD are seven times more likely to have a DSM-IV diagnosis of marijuana dependence than individuals without SAD [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p>Individuals with SAD are highly vulnerable to SUDs [<a href="#rid27">27</a>]. Data on 8841 patients with SAD from the Australian National Survey of Mental Health and Wellbeing found that SAD is the most common anxiety disorder among individuals with SUDs (33.3 to 36.0 percent) [<a href="#rid10">10</a>]. Research shows that socially phobic individuals are two to three times more likely than individuals without SAD to develop an alcohol use disorder [<a href="#rid26">26</a>]. The onset of SAD typically precedes the development of the SUD [<a href="#rid39">39</a>], and up to 16.4 percent of socially phobic individuals endorse self-medicating anxiety symptoms with alcohol and drugs [<a href="#rid40">40</a>]. A prospective study of 627 individuals found that SAD was associated with the subsequent onset of alcohol use disorder; PTSD was associated with a subsequent onset of an SUD [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H18656367"><span class="h2">Obsessive-compulsive disorder</span><span class="headingEndMark"> — </span>There is mixed evidence for whether individuals with OCD have a higher rate of co-occurring SUDs than the general population:</p><p class="bulletIndent1"><span class="glyph">●</span>A large epidemiological study of six geographic areas in the United States found no difference between rates of OCD among individuals with a DSM-IV diagnosis of alcohol dependence compared with a control group without alcohol dependence [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two studies of patients receiving psychiatric treatment in the United States found that 1.3 to 4.0 percent of patients with OCD met criteria for a lifetime SUD [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, a survey of 25,097 adults from the Canadian Community Health Survey found that individuals with OCD were significantly more likely to have current (past 12 months) and lifetime alcohol and drug use disorders compared with individuals without OCD [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A smaller survey study of 430 undergraduate students in the United States found that increased OCD symptom severity was associated with increased cannabis misuse [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H20550111"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Emergent data suggest that substance use disorders (SUDs) and anxiety disorders share common neurobiological substrates that include the hypothalamic pituitary adrenal (HPA) axis and noradrenergic system.</p><p class="headingAnchor" id="H20550118"><span class="h2">Hypothalamic pituitary adrenal (HPA) axis</span><span class="headingEndMark"> — </span>While the findings on HPA axis reactivity are mixed, a preponderance of evidence suggests that a disruption in normal HPA hormonal feedback is a common physical feature of both substance use and anxiety disorders. More specifically, these studies suggest that a hyperactive HPA axis occurs as a function of long-term drug use and/or prolonged stress exposure.</p><p>The HPA axis has been implicated in behaviors associated with an SUD. As an example, stress is a powerful predictor of relapse, and perturbations within the HPA axis as a result of long-term drug exposure are hypothesized to culminate in an addictive phenotype [<a href="#rid47">47,48</a>]. Even acute drug exposure in drug-naïve humans and rodents increases circulating HPA hormone levels [<a href="#rid49">49</a>]. Clinical studies of men and women with a diagnosis of cocaine dependence demonstrate that corticotropin releasing hormone (CRH) promotes drug craving and subjective stress [<a href="#rid50">50</a>]. </p><p>Studies of posttraumatic stress disorder (PTSD) and HPA axis reactivity are complex and have yielded equivocal findings [<a href="#rid51">51</a>]. Findings from studies of patients with PTSD have been mixed. For example, compared with healthy controls, patients with PTSD have higher, lower and normal 24-hour urinary cortisol levels [<a href="#rid52">52-54</a>]. However, the majority of studies support enhanced glucocorticoid negative feedback in patients with PTSD, suggesting a hyperactive physiological stress system. As an example, clinical studies have shown elevated lymphocyte glucocorticoid receptor levels in patients with PTSD and enhanced suppression of cortisol following a <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> challenge, as well as elevated ACTH levels following a <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> challenge [<a href="#rid55">55-57</a>]. Patients with PTSD exhibit higher levels of cerebral spinal fluid CRH than healthy controls. The hyperactive HPA hormonal response is thought to be involved in hyperarousal that is commonly observed in PTSD patients [<a href="#rid58">58</a>].</p><p>Studies of the HPA axis in individuals with panic disorder, generalized anxiety disorder (GAD), and social anxiety disorder (SAD) have been inconclusive. As an example, one study found that individuals with panic disorder exhibited a similar HPA hormone response to <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> and metyrapone plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> as controls [<a href="#rid59">59</a>]. Another study found higher diurnal cortisol levels in individuals with panic disorder than controls [<a href="#rid60">60</a>]. Elevated [<a href="#rid61">61</a>] and normal [<a href="#rid62">62</a>] basal cortisol levels have been reported among individuals with GAD. Dexamethasone challenge results in patients with GAD are difficult to interpret, as greater non-suppression [<a href="#rid63">63</a>] and normal suppression [<a href="#rid64">64</a>] have been reported. Similar salivary cortisol levels were found between patients with SAD and healthy controls following electrical stimulation [<a href="#rid65">65</a>].</p><p>Findings regarding HPA axis functioning in patients with obsessive-compulsive disorder (OCD) are mixed. As an example, both cortisol suppression and nonsuppression have been found in OCD patients in response to a <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> challenge [<a href="#rid66">66,67</a>]. Both higher [<a href="#rid68">68</a>] and normal CRH [<a href="#rid69">69</a>] levels have been reported in the cerebral spinal fluid of OCD patients [<a href="#rid68">68,69</a>]. However, other studies have been more conclusive demonstrating elevated cortisol, dehydroepiandrosterone, and ACTH concentrations and higher 24-hour urinary cortisol levels in OCD patients [<a href="#rid70">70-72</a>].</p><p class="headingAnchor" id="H20550125"><span class="h2">Noradrenaline systems</span><span class="headingEndMark"> — </span>Animal models of addiction have demonstrated that norepinephrine plays a critical role in the transition from recreational drug use to an SUD [<a href="#rid73">73</a>]. Dopamine beta-hydroxylase inhibitors attenuate alcohol intake in rodents [<a href="#rid74">74</a>]. Alpha1-noradrenergic receptor antagonists prevent escalation of drug seeking behavior [<a href="#rid75">75,76</a>]. Noradrenergic activity has been linked to anxiety and negative affect during opiate withdrawal [<a href="#rid77">77</a>]. Noradrenergic activity has been associated with drug craving and relapse in cocaine-dependent individuals [<a href="#rid78">78,79</a>].</p><p>Compared with healthy controls, PTSD patients have a lower number of platelet positive alpha2-adrenergic receptors, and higher 24-hour urinary norepinephrine levels. Compared with controls, PTSD patients showed increases in salivary alpha amylase upon awakening. Patterns of salivary alpha amylase secretion were positively associated with symptoms of PTSD [<a href="#rid80">80</a>]. PTSD patients exhibit a sensitized cardiovascular response to the alpha2-receptor antagonist yohimbine [<a href="#rid81">81</a>]. Medications that attenuate noradrenergic activity have been the used to treat symptoms of PTSD [<a href="#rid82">82,83</a>].</p><p>The strongest evidence for a role of noradrenergic systems in mediating symptoms of GAD may be from pharmacotherapy trials, which have found serotonin- norepinephrine reuptake inhibitors (SNRIs) to be effective in the treatment of GAD [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/z/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management", section on 'Initial Pharmacotherapy'</a>.)</p><p>Yohimbine produces panic-like symptoms in healthy controls [<a href="#rid85">85</a>]. Administration of yohimbine to individuals with panic disorder caused greater increases in norepinephrine turnover than in healthy controls [<a href="#rid86">86</a>]. SNRIs are clinically effective at attenuating symptoms of panic disorder [<a href="#rid87">87</a>]. Patients with SAD exhibit greater salivary alpha amylase in response to electrical stimulation compared with healthy controls [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/108804.html" rel="external">"Management of panic disorder with or without agoraphobia in adults"</a>.)</p><p>Few, limited studies have examined noradrenergic dysregulation in patients with OCD, with inconclusive results. Data from the existing studies are inconclusive. A study found no difference in behavioral or noradrenergic responses to yohimbine between OCD patients and healthy controls [<a href="#rid88">88</a>]. Another study has shown elevated plasma norepinephrine levels in OCD patients [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H20550132"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Individuals with a co-occurring substance use disorder and an anxiety-related disorder on average present with a more severe clinical profile as compared to individuals with either disorder alone [<a href="#rid90">90,91</a>]. As an example, research involving individuals seeking treatment has demonstrated that individuals with DSM-IV cocaine dependence and posttraumatic stress disorder (PTSD), as compared to individuals without PTSD, present with more severe depression, vocational impairment, interpersonal dysfunction, medical problems, and other Axis I and II disorders.</p><p>Substance use, physiologic dependence, and withdrawal can mimic or exacerbate symptoms of anxiety.</p><p class="bulletIndent1"><span class="glyph">●</span>Stimulants, in particular, can cause heart palpitations, trembling or shaking, sweating, dizziness or feeling faint, depersonalization, paresthesias, nausea, and hot flushes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal from substances such as opioids, alcohol, and benzodiazepines, can generate anxiety symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Opiate withdrawal is characterized by insomnia, nausea, and diarrhea, but may be distinguished from independent anxiety by the often severe muscle aches, vomiting and fever. (See  <a class="medical medical_review" href="/z/d/html/306.html" rel="external">"Opioid withdrawal in the emergency setting"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol and benzodiazepine withdrawal may also generate anxiety symptoms, such as insomnia, psychomotor agitation, tachycardia, perspiration, nausea, and tremor. (See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H20550139"><span class="h1">COURSE</span><span class="headingEndMark"> — </span>The median age of onset for DSM-IV diagnoses of alcohol and other drug dependence has been estimated at 23 and 21 years of age, respectively [<a href="#rid24">24</a>]. The median age of onset for anxiety-related disorders ranges from 7 years old for specific phobia to 31 years old for generalized anxiety disorder. However, a 2018 study of 13,984 college students from eight countries found a median age of onset of 15.6 years for alcohol use disorders and 16.2 years for SUD. Average age of onset for both GAD and panic disorder was 14.9 years old. The authors suggest that the discrepancy in age of onset in these results compared with the National Comorbidity Survey Replication [<a href="#rid24">24</a>] results may be related to several factors including the range of age of the sample for each study (college students versus 18 to 65 years old) [<a href="#rid92">92</a>].</p><p>In the majority of cases, the anxiety-related disorder is temporally primary, meaning that the onset of the anxiety-related disorder precedes the onset of the substance use disorder (SUD) [<a href="#rid2">2,16,26,93</a>]. An analysis of data from several epidemiologic studies found that among individuals with DSM-IV diagnoses of both alcohol dependence and an anxiety disorder, the anxiety disorder preceded alcohol dependence in 56.7 to 79.4 percent of cases [<a href="#rid94">94</a>]. Among individuals with DSM-IV diagnoses of both drug dependence and an anxiety disorder, the anxiety disorder preceded drug dependence in 67.6 percent to 100 percent of cases [<a href="#rid94">94</a>].</p><p>This temporal ordering of onset suggests that anxiety-related disorders predispose individuals to developing SUDs later in life; however, available evidence does not allow for definitive conclusions on causality [<a href="#rid26">26,93</a>]. This link between anxiety-related disorders and SUDs may be related to self-medication of anxiety symptoms, shared neurobiological connections, or genetic predispositions.</p><p>Both SUDs and anxiety-related disorders are chronic, relapsing conditions. Comorbid SUDs and anxiety-related disorders are more chronic than non-comorbid substance use or anxiety-related disorders, and are associated with increased likelihood of poverty, homelessness, being the victim or perpetrator of abuse, and risk of death by homicide, suicide or accidental means [<a href="#rid2">2,22</a>].</p><p class="headingAnchor" id="H20550146"><span class="h1">ASSESSMENT AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Differentiating diagnostically between a substance-induced state and a true anxiety-related disorder needs to be addressed in the psychiatric examination. Most of the time, however, the co-occurring anxiety disorder will be independent and will not be a substance-induced anxiety disorder. In patients with a co-occurring substance use disorder (SUD) and independent anxiety-related disorder from a nationally representative sample of the United States population, only a few individuals experienced current anxiety disorders that were only substance induced. These findings strongly suggest that co-occurring anxiety-related disorders among patients with a SUD be targeted in treatment. Otherwise, the anxiety symptoms will continue to serve as a trigger for relapse [<a href="#rid4">4</a>].</p><p>Presentations can be challenging to diagnose due to several areas of overlapping manifestations:</p><p class="bulletIndent1"><span class="glyph">●</span>The active use of some substances, such as stimulants, may produce anxiety states that mimic true anxiety disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal from some substances, such as opiates and benzodiazepines, lead to anxiety states.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The chronic use of drugs and alcohol exerts a powerful influence on neurotransmitter systems related to the development of anxiety-related disorders, and may unmask a biological susceptibility or lead to neurobiologic changes over time that manifest as anxiety disorders.</p><p></p><p>Clinical assessment needs to consider illicit drugs, caffeine, nicotine, and over-the-counter medications such as <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">pseudoephedrine</a> and diet pills, all of which may produce substantial anxiety, irritability and panic attacks [<a href="#rid95">95</a>], and mimic the symptoms of panic disorder and drug withdrawal [<a href="#rid96">96,97</a>]. Decreasing consumption of these substances may help to significantly decrease anxiety. As an example, patients with panic disorder may find that reducing their consumption of caffeinated sodas, coffees and teas leads to a decrease in the frequency and severity of their panic attacks.</p><p>Clinical observation during a period of abstinence from substances can distinguish a substance-induced, transient state from a true anxiety disorder. The duration of abstinence necessary for accurate diagnosis varies depending on the substance.</p><p class="bulletIndent1"><span class="glyph">●</span>For substances with a long half-life (eg, benzodiazepines such as <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>), withdrawal symptoms may be protracted. Several weeks of abstinence may be needed to distinguish anxiety stemming from withdrawal from an independent anxiety disorder [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For substances with a shorter half-life (eg, alcohol and cocaine), accurate diagnosis may be possible after a shorter period of abstinence (eg, 30 days) [<a href="#rid99">99</a>].</p><p></p><p>Several questions may help differentiate between a substance-induced state and a true anxiety disorder. Endorsement of the following questions supports a primary anxiety diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Were the anxiety symptoms present before substance use commenced?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Were anxiety symptoms present during periods of sobriety greater than one to three months?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is there a positive family history of anxiety disorders?</p><p></p><p class="headingAnchor" id="H16814853"><span class="h2">Generalized anxiety disorder</span><span class="headingEndMark"> — </span>Generalized anxiety disorder (GAD) in particular can be difficult to diagnose in the presence of active substance use. Symptoms of GAD, which include anxiety, worry, restlessness, fatigue, irritability, poor concentration, muscle tension, and sleep impairment, can be mimicked by substance use. To accurately diagnose GAD, the assessment should be delayed until intoxication or withdrawal has terminated. Reassessment of the patient after a period of prolonged abstinence can confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p>Early identification of drug or alcohol use among patients with GAD is critical, because GAD is associated with significantly faster progression from initial substance use to the development of an SUD. In a study of 1,269 adolescents and young adults, GAD was associated with a 3.5-fold increase in rate of progression from first drink to the onset of alcohol dependence [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H16814860"><span class="h2">Obsessive-compulsive disorder</span><span class="headingEndMark"> — </span>Obsessive-compulsive disorder (OCD) has symptoms that overlap with SUDs. However, while SUDs are characterized by elements of obsessive thinking and compulsive behaviors [<a href="#rid101">101</a>], a diagnosis of OCD is differentiated by the focus of the obsessions and compulsions. Patients with OCD endorse thoughts centered on contamination or doubt. Patients with SUDs endorse intrusive thoughts centered on alcohol or drugs, feel compelled to use alcohol or drugs, and may feel that if they use substances, the distressing thoughts or compulsions to use will be quelled. The use of substances is connected in a realistic way with the cravings that patients with SUDs experience. (See  <a class="medical medical_review" href="/z/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H16814871"><span class="h2">Panic disorder</span><span class="headingEndMark"> — </span>Differential diagnosis of panic disorder and SUDs can be complicated by the fact that acute intoxication or withdrawal from alcohol, stimulants, and opioids can precipitate panic-like symptoms [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/z/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis", section on 'Assessment'</a>.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Heavy alcohol use increases sensitivity to carbon dioxide, thereby increasing the possibility of a panic attack [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of noradrenergic stimulation, the use of stimulants may induce panic attacks [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety is observed during withdrawal from sedatives.</p><p></p><p class="headingAnchor" id="H2348985"><span class="h2">Other anxiety disorders</span><span class="headingEndMark"> — </span>Substance-induced anxiety can be distinguished from social anxiety disorder (SAD) by the latter’s requirement for the presence of a fear of public scrutiny, which is not mimicked by substance use, intoxication, or withdrawal. In addition, symptoms of SAD usually present early in life, before the onset of substance use. (See  <a class="medical medical_review" href="/z/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H855448228"><span class="h2">Posttraumatic stress disorder</span><span class="headingEndMark"> — </span>Symptoms of posttraumatic stress disorder (PTSD) result from exposure to a traumatic life event (eg, physical or sexual assault, natural disaster, serious accident, combat experiences). Intrusive thoughts or images related to the trauma are unlikely to be mimicked by substance use, intoxication or withdrawal. Hyperarousal symptoms of PTSD (eg, irritability, sleep impairment, difficulty concentrating, exaggerated startle response) as well as negative alterations in mood and cognition can be mimicked or exacerbated by the use of or withdrawal from alcohol and drugs. (See  <a class="medical medical_review" href="/z/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3377098869"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114814.html" rel="external">"Society guideline links: Benzodiazepine use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114306.html" rel="external">"Society guideline links: Alcohol use disorders and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115010.html" rel="external">"Society guideline links: Stimulant use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114308.html" rel="external">"Society guideline links: Cannabis use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113096.html" rel="external">"Society guideline links: Anxiety and anxiety disorders in adults"</a>.)</p><p class="headingAnchor" id="H16815232"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Substance use disorders (SUDs) have been found to co-occur at an increased rate in posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder (SAD). In most instances, the anxiety disorder onset precedes that of the SUD(s). Results regarding obsessive-compulsive disorder (OCD) and SUDs are mixed. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preclinical studies demonstrate that SUDs and anxiety-related disorders share common neurobiological substrates that include disruptions within the hypothalamic-pituitary-adrenal (HPA) axis and noradrenergic systems. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with co-occurring SUDs and anxiety-related disorders present with a more severe clinical profile and greater chronicity as compared to individuals with either disorder alone. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical observation during a period of prolonged abstinence from substances can distinguish a transient, substance-induced state from a true anxiety disorder. The duration of abstinence necessary for accurate diagnosis varies depending on the substance. (See <a class="local">'Assessment and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Substances with a long half-life (eg, <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>) may require several weeks of abstinence to make an accurate diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Substances with a shorter half-life (eg, alcohol and cocaine), can generally be accurately diagnosed after approximately 30 days of abstinence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tips for distinguishing anxiety-related disorders from the effects of substance intoxication or withdrawal differ by disorder:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most of the symptoms of generalized anxiety disorder can be mimicked by substance use. Assessment should be delayed until symptoms of intoxication or withdrawal have resolved. (See <a class="local">'Generalized anxiety disorder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In contrast with OCD, obsessive thinking and compulsive behaviors that occur secondary to a SUD center on the substances used. (See <a class="local">'Obsessive-compulsive disorder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Substances, stimulants in particular, can induce panic attacks. In contrast to panic experienced in the context of SUDs, attacks characteristic of panic disorder occur unexpectedly, and patients experience persistent worry about having another attack. (See <a class="local">'Panic disorder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperarousal symptoms of PTSD (eg, irritability, sleep impairment, difficulty concentrating, exaggerated startle response) can be exacerbated by the use of, or withdrawal from, alcohol and drugs. (See <a class="local">'Other anxiety disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The primary feature of SAD, fear of public scrutiny, is not typically mimicked by substance use, intoxication, or withdrawal. Symptoms of SAD that present only in the context of intoxication or withdrawal are not sufficient to meet criteria for a diagnosis of SAD. (See <a class="local">'Other anxiety disorders'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.</a></li><li><a class="nounderline abstract_t">Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.</a></li><li><a class="nounderline abstract_t">Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64:566.</a></li><li><a class="nounderline abstract_t">Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61:807.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li><a class="nounderline abstract_t">Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72:757.</a></li><li><a class="nounderline abstract_t">Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 drug use disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry 2016; 73:39.</a></li><li><a class="nounderline abstract_t">Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord 2011; 25:456.</a></li><li><a class="nounderline abstract_t">Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048.</a></li><li><a class="nounderline abstract_t">Prior K, Mills K, Ross J, Teesson M. Substance use disorders comorbid with mood and anxiety disorders in the Australian general population. Drug Alcohol Rev 2017; 36:317.</a></li><li><a class="nounderline abstract_t">Barry DT, Cutter CJ, Beitel M, et al. Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder. J Clin Psychiatry 2016; 77:1413.</a></li><li><a class="nounderline abstract_t">Breslau N, Davis GC, Andreski P, Peterson E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991; 48:216.</a></li><li><a class="nounderline abstract_t">Breslau N, Davis GC, Peterson EL, Schultz L. Psychiatric sequelae of posttraumatic stress disorder in women. Arch Gen Psychiatry 1997; 54:81.</a></li><li><a class="nounderline abstract_t">Cottler LB, Compton WM 3rd, Mager D, et al. Posttraumatic stress disorder among substance users from the general population. Am J Psychiatry 1992; 149:664.</a></li><li><a class="nounderline abstract_t">Hassan AN, Le Foll B, Imtiaz S, Rehm J. The effect of post-traumatic stress disorder on the risk of developing prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. Drug Alcohol Depend 2017; 179:260.</a></li><li><a class="nounderline abstract_t">Berenz EC, Roberson-Nay R, Latendresse SJ, et al. Posttraumatic stress disorder and alcohol dependence: Epidemiology and order of onset. Psychol Trauma 2017; 9:485.</a></li><li><a class="nounderline abstract_t">Hoge CW, Auchterlonie JL, Milliken CS. Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan. JAMA 2006; 295:1023.</a></li><li><a class="nounderline abstract_t">Milliken CS, Auchterlonie JL, Hoge CW. Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war. JAMA 2007; 298:2141.</a></li><li><a class="nounderline abstract_t">Hoge CW, Riviere LA, Wilk JE, et al. The prevalence of post-traumatic stress disorder (PTSD) in US combat soldiers: a head-to-head comparison of DSM-5 versus DSM-IV-TR symptom criteria with the PTSD checklist. Lancet Psychiatry 2014; 1:269.</a></li><li><a class="nounderline abstract_t">Jacobson IG, Ryan MA, Hooper TI, et al. Alcohol use and alcohol-related problems before and after military combat deployment. JAMA 2008; 300:663.</a></li><li><a class="nounderline abstract_t">Wilk JE, Bliese PD, Kim PY, et al. Relationship of combat experiences to alcohol misuse among U.S. soldiers returning from the Iraq war. Drug Alcohol Depend 2010; 108:115.</a></li><li><a class="nounderline abstract_t">Norman SB, Haller M, Hamblen JL, et al. The burden of co-occurring alcohol use disorder and PTSD in U.S. Military veterans: Comorbidities, functioning, and suicidality. Psychol Addict Behav 2018; 32:224.</a></li><li><a class="nounderline abstract_t">Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl 8:24.</a></li><li><a class="nounderline abstract_t">Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.</a></li><li><a class="nounderline abstract_t">Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005; 35:1747.</a></li><li><a class="nounderline abstract_t">Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 1990; 147:685.</a></li><li><a class="nounderline abstract_t">Sareen J, Chartier M, Paulus MP, Stein MB. Illicit drug use and anxiety disorders: findings from two community surveys. Psychiatry Res 2006; 142:11.</a></li><li><a class="nounderline abstract_t">Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511.</a></li><li><a class="nounderline abstract_t">de Jonge P, Roest AM, Lim CC, et al. Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys. Depress Anxiety 2016; 33:1155.</a></li><li><a class="nounderline abstract_t">Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54:313.</a></li><li><a class="nounderline abstract_t">Canino GJ, Bird HR, Shrout PE, et al. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry 1987; 44:727.</a></li><li><a class="nounderline abstract_t">Angst J, Dobler-Mikola A, Binder J. The Zurich study--a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. I. Problem, methodology. Eur Arch Psychiatry Neurol Sci 1984; 234:13.</a></li><li><a class="nounderline abstract_t">Swendsen JD, Merikangas KR, Canino GJ, et al. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry 1998; 39:176.</a></li><li><a class="nounderline abstract_t">O'Brien MS, Wu LT, Anthony JC. Cocaine use and the occurrence of panic attacks in the community: a case-crossover approach. Subst Use Misuse 2005; 40:285.</a></li><li><a class="nounderline abstract_t">Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67:247.</a></li><li><a class="nounderline abstract_t">Zimmermann P, Wittchen HU, Höfler M, et al. Primary anxiety disorders and the development of subsequent alcohol use disorders: a 4-year community study of adolescents and young adults. Psychol Med 2003; 33:1211.</a></li><li><a class="nounderline abstract_t">Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66:1351.</a></li><li><a class="nounderline abstract_t">Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 2002; 28:643.</a></li><li><a class="nounderline abstract_t">Carrigan MH, Randall CL. Self-medication in social phobia: a review of the alcohol literature. Addict Behav 2003; 28:269.</a></li><li><a class="nounderline abstract_t">Bolton J, Cox B, Clara I, Sareen J. Use of alcohol and drugs to self-medicate anxiety disorders in a nationally representative sample. J Nerv Ment Dis 2006; 194:818.</a></li><li><a class="nounderline abstract_t">Wolitzky-Taylor K, Bobova L, Zinbarg RE, et al. Longitudinal investigation of the impact of anxiety and mood disorders in adolescence on subsequent substance use disorder onset and vice versa. Addict Behav 2012; 37:982.</a></li><li><a class="nounderline abstract_t">Schuckit MA, Tipp JE, Bucholz KK, et al. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction 1997; 92:1289.</a></li><li><a class="nounderline abstract_t">Sbrana A, Bizzarri JV, Rucci P, et al. The spectrum of substance use in mood and anxiety disorders. Compr Psychiatry 2005; 46:6.</a></li><li><a class="nounderline abstract_t">Schuckit MA, Tipp JE, Bergman M, et al. Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am J Psychiatry 1997; 154:948.</a></li><li><a class="nounderline abstract_t">Osland S, Arnold PD, Pringsheim T. The prevalence of diagnosed obsessive compulsive disorder and associated comorbidities: A population-based Canadian study. Psychiatry Res 2018; 268:137.</a></li><li><a class="nounderline abstract_t">Spradlin A, Mauzay D, Cuttler C. Symptoms of obsessive-compulsive disorder predict cannabis misuse. Addict Behav 2017; 72:159.</a></li><li><a class="nounderline abstract_t">Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) 2001; 158:343.</a></li><li><a class="nounderline abstract_t">Erb S, Shaham Y, Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology (Berl) 1996; 128:408.</a></li><li><a class="nounderline abstract_t">Moldow RL, Fischman AJ. Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone. Peptides 1987; 8:819.</a></li><li><a class="nounderline abstract_t">Brady KT, McRae AL, Moran-Santa Maria MM, et al. Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. Arch Gen Psychiatry 2009; 66:422.</a></li><li><a class="nounderline abstract_t">Tollefson S, Himes M, Narendran R. Imaging corticotropin-releasing-factor and nociceptin in addiction and PTSD models. Int Rev Psychiatry 2017; 29:567.</a></li><li><a class="nounderline abstract_t">Maes M, Lin A, Bonaccorso S, et al. Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998; 98:328.</a></li><li><a class="nounderline abstract_t">Mason JW, Giller EL, Kosten TR, et al. Urinary free-cortisol levels in posttraumatic stress disorder patients. J Nerv Ment Dis 1986; 174:145.</a></li><li><a class="nounderline abstract_t">Baker DG, West SA, Nicholson WE, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999; 156:585.</a></li><li><a class="nounderline abstract_t">Yehuda R, Lowy MT, Southwick SM, et al. Lymphocyte glucocorticoid receptor number in posttraumatic stress disorder. Am J Psychiatry 1991; 148:499.</a></li><li><a class="nounderline abstract_t">Yehuda R, Boisoneau D, Lowy MT, Giller EL Jr. Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder. Arch Gen Psychiatry 1995; 52:583.</a></li><li><a class="nounderline abstract_t">Yehuda R, Levengood RA, Schmeidler J, et al. Increased pituitary activation following metyrapone administration in post-traumatic stress disorder. Psychoneuroendocrinology 1996; 21:1.</a></li><li><a class="nounderline abstract_t">Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997; 154:624.</a></li><li><a class="nounderline abstract_t">Kellner M, Schick M, Yassouridis A, et al. Metyrapone tests in patients with panic disorder. Biol Psychiatry 2004; 56:898.</a></li><li><a class="nounderline abstract_t">Abelson JL, Curtis GC. Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 1996; 53:323.</a></li><li><a class="nounderline abstract_t">Mantella RC, Butters MA, Amico JA, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 2008; 33:773.</a></li><li><a class="nounderline abstract_t">Rosenbaum AH, Schatzberg AF, Jost FA 3rd, et al. Urinary free cortisol levels in anxiety. Psychosomatics 1983; 24:835.</a></li><li><a class="nounderline abstract_t">Okasha A, Bishry Z, Khalil AH, et al. Panic disorder. An overlapping or independent entity? Br J Psychiatry 1994; 164:818.</a></li><li><a class="nounderline abstract_t">Tiller JW, Biddle N, Maguire KP, Davies BM. The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 1988; 23:261.</a></li><li><a class="nounderline abstract_t">Tamura A, Maruyama Y, Ishitobi Y, et al. Salivary alpha-amylase and cortisol responsiveness following electrical stimulation stress in patients with the generalized type of social anxiety disorder. Pharmacopsychiatry 2013; 46:225.</a></li><li><a class="nounderline abstract_t">Catapano F, Monteleone P, Maj M, Kemali D. Dexamethasone suppression test in patients with primary obsessive-compulsive disorder and in healthy controls. Neuropsychobiology 1990; 23:53.</a></li><li><a class="nounderline abstract_t">Coryell WH, Black DW, Kelly MW, Noyes R Jr. HPA axis disturbance in obsessive-compulsive disorder. Psychiatry Res 1989; 30:243.</a></li><li><a class="nounderline abstract_t">Altemus M, Pigott T, Kalogeras KT, et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:9.</a></li><li><a class="nounderline abstract_t">Chappell P, Leckman J, Goodman W, et al. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry 1996; 39:776.</a></li><li><a class="nounderline abstract_t">Gehris TL, Kathol RG, Black DW, Noyes R Jr. Urinary free cortisol levels in obsessive-compulsive disorder. Psychiatry Res 1990; 32:151.</a></li><li><a class="nounderline abstract_t">Kluge M, Schüssler P, Künzel HE, et al. Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. J Psychiatr Res 2007; 41:928.</a></li><li><a class="nounderline abstract_t">Erbay LG, Kartalci S. Neurosteroid Levels in Patients with Obsessive-Compulsive Disorder. Psychiatry Investig 2015; 12:538.</a></li><li><a class="nounderline abstract_t">Koob GF. Brain stress systems in the amygdala and addiction. Brain Res 2009; 1293:61.</a></li><li><a class="nounderline abstract_t">Amit Z, Brown ZW, Levitan DE, Ogren SO. Noradrenergic mediation of the positive reinforcing properties of ethanol: I. Suppression of ethanol consumption in laboratory rats following dopamine-beta-hydroxylase inhibition. Arch Int Pharmacodyn Ther 1977; 230:65.</a></li><li><a class="nounderline abstract_t">Walker BM, Rasmussen DD, Raskind MA, Koob GF. alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 2008; 42:91.</a></li><li><a class="nounderline abstract_t">Wee S, Mandyam CD, Lekic DM, Koob GF. Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur Neuropsychopharmacol 2008; 18:303.</a></li><li><a class="nounderline abstract_t">Delfs JM, Zhu Y, Druhan JP, Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 2000; 403:430.</a></li><li><a class="nounderline abstract_t">Moran-Santa Maria MM, McRae-Clark A, Baker NL, et al. Yohimbine administration and cue-reactivity in cocaine-dependent individuals. Psychopharmacology (Berl) 2014; 231:4157.</a></li><li><a class="nounderline abstract_t">Fox HC, Morgan PT, Sinha R. Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. Neuropsychopharmacology 2014; 39:1527.</a></li><li><a class="nounderline abstract_t">Thoma MV, Joksimovic L, Kirschbaum C, et al. Altered salivary alpha-amylase awakening response in Bosnian War refugees with posttraumatic stress disorder. Psychoneuroendocrinology 2012; 37:810.</a></li><li><a class="nounderline abstract_t">Southwick SM, Bremner JD, Rasmusson A, et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 46:1192.</a></li><li><a class="nounderline abstract_t">Agren H. Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory. Acta Psychiatr Scand Suppl 1986; 327:91.</a></li><li><a class="nounderline abstract_t">Green B. Prazosin in the treatment of PTSD. J Psychiatr Pract 2014; 20:253.</a></li><li><a class="nounderline abstract_t">Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23:523.</a></li><li><a class="nounderline abstract_t">Vasa RA, Pine DS, Masten CL, et al. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology (Berl) 2009; 204:445.</a></li><li><a class="nounderline abstract_t">Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986; 43:1042.</a></li><li><a class="nounderline abstract_t">Freire RC, Hallak JE, Crippa JA, Nardi AE. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother 2011; 12:1419.</a></li><li><a class="nounderline abstract_t">Rasmussen SA, Goodman WK, Woods SW, et al. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology (Berl) 1987; 93:308.</a></li><li><a class="nounderline abstract_t">Fluitman SB, Denys DA, Heijnen CJ, Westenberg HG. Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder. Psychoneuroendocrinology 2010; 35:906.</a></li><li><a class="nounderline abstract_t">Najavits LM, Weiss RD, Shaw SR, Muenz LR. "Seeking safety": outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. J Trauma Stress 1998; 11:437.</a></li><li><a class="nounderline abstract_t">Back SE, Dansky BS, Carroll KM, et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: description of procedures. J Subst Abuse Treat 2001; 21:35.</a></li><li><a class="nounderline abstract_t">Auerbach RP, Mortier P, Bruffaerts R, et al. WHO World Mental Health Surveys International College Student Project: Prevalence and distribution of mental disorders. J Abnorm Psychol 2018; 127:623.</a></li><li><a class="nounderline abstract_t">Compton WM 3rd, Cottler LB, Phelps DL, et al. Psychiatric disorders among drug dependent subjects: are they primary or secondary? Am J Addict 2000; 9:126.</a></li><li><a class="nounderline abstract_t">Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav 1998; 23:893.</a></li><li class="breakAll">Uhde TW. Effects of caffeine pn anxiety and depression. In: Neurobiology of Panic Disorder, Ballenger JC (Ed), Wiley-Liss, New York 1990. p.219.</li><li><a class="nounderline abstract_t">Kendler KS, Myers J, O Gardner C. Caffeine intake, toxicity and dependence and lifetime risk for psychiatric and substance use disorders: an epidemiologic and co-twin control analysis. Psychol Med 2006; 36:1717.</a></li><li><a class="nounderline abstract_t">Veleber DM, Templer DI. Effects of caffeine on anxiety and depression. J Abnorm Psychol 1984; 93:120.</a></li><li><a class="nounderline abstract_t">Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18:249.</a></li><li><a class="nounderline abstract_t">Quello SB, Brady KT, Sonne SC. Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect 2005; 3:13.</a></li><li><a class="nounderline abstract_t">Sartor CE, Lynskey MT, Heath AC, et al. The role of childhood risk factors in initiation of alcohol use and progression to alcohol dependence. Addiction 2007; 102:216.</a></li><li><a class="nounderline abstract_t">Modell JG, Glaser FB, Cyr L, Mountz JM. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res 1992; 16:272.</a></li><li><a class="nounderline abstract_t">Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992; 32:91.</a></li><li><a class="nounderline abstract_t">Cosci F, Schruers KR, Abrams K, Griez EJ. Alcohol use disorders and panic disorder: a review of the evidence of a direct relationship. J Clin Psychiatry 2007; 68:874.</a></li><li><a class="nounderline abstract_t">Louie AK, Lannon RA, Rutzick EA, et al. Clinical features of cocaine-induced panic. Biol Psychiatry 1996; 40:938.</a></li></ol></div><div id="topicVersionRevision">Topic 14850 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8279933" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939839" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485608" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289279" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289279" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26039070" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of DSM-5 alcohol use disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580136" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of DSM-5 drug use disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21168991" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492257" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Posttraumatic stress disorder in the National Comorbidity Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27324816" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Substance use disorders comorbid with mood and anxiety disorders in the Australian general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574837" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996917" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Traumatic events and posttraumatic stress disorder in an urban population of young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006404" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Psychiatric sequelae of posttraumatic stress disorder in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1575258" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Posttraumatic stress disorder among substance users from the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28818717" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The effect of post-traumatic stress disorder on the risk of developing prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27617659" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Posttraumatic stress disorder and alcohol dependence: Epidemiology and order of onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507803" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000197" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26360860" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The prevalence of post-traumatic stress disorder (PTSD) in US combat soldiers: a head-to-head comparison of DSM-5 versus DSM-IV-TR symptom criteria with the PTSD checklist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18698065" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Alcohol use and alcohol-related problems before and after military combat deployment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20060237" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Relationship of combat experiences to alcohol misuse among U.S. soldiers returning from the Iraq war.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29553778" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The burden of co-occurring alcohol use disorder and PTSD in U.S. Military veterans: Comorbidities, functioning, and suicidality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044105" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Generalized anxiety and depression in primary care: prevalence, recognition, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939837" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16202187" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188513" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The relation between alcohol problems and the anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16712953" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Illicit drug use and anxiety disorders: findings from two community surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2232018" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27775828" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9107147" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3498456" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The prevalence of specific psychiatric disorders in Puerto Rico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6333343" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Zurich study--a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. I. Problem, methodology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9675501" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15776977" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cocaine use and the occurrence of panic attacks in the community: a case-crossover approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16566620" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14580076" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary anxiety disorders and the development of subsequent alcohol use disorders: a 4-year community study of adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16420070" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492261" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12573678" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Self-medication in social phobia: a review of the alcohol literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17102705" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of alcohol and drugs to self-medicate anxiety disorders in a nationally representative sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503436" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Longitudinal investigation of the impact of anxiety and mood disorders in adolescence on subsequent substance use disorder onset and vice versa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9489046" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15714188" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The spectrum of substance use in mood and anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9210745" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comparison of induced and independent major depressive disorders in 2,945 alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30025284" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The prevalence of diagnosed obsessive compulsive disorder and associated comorbidities: A population-based Canadian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28453999" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Symptoms of obsessive-compulsive disorder predict cannabis misuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11797055" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : How does stress increase risk of drug abuse and relapse?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8986011" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829143" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349312" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29231765" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Imaging corticotropin-releasing-factor and nociceptin in addiction and PTSD models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9821456" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3950596" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Urinary free-cortisol levels in posttraumatic stress disorder patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200738" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006697" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lymphocyte glucocorticoid receptor number in posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598635" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8778898" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Increased pituitary activation following metyrapone administration in post-traumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137116" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15576069" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Metyrapone tests in patients with panic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634010" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18407426" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6647727" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Urinary free cortisol levels in anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864948" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Panic disorder. An overlapping or independent entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3337861" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23975855" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Salivary alpha-amylase and cortisol responsiveness following electrical stimulation stress in patients with the generalized type of social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2077433" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dexamethasone suppression test in patients with primary obsessive-compulsive disorder and in healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694203" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : HPA axis disturbance in obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1370198" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8731518" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2367600" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Urinary free cortisol levels in obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17049559" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26508966" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Neurosteroid Levels in Patients with Obsessive-Compulsive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332030" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Brain stress systems in the amygdala and addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/603310" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Noradrenergic mediation of the positive reinforcing properties of ethanol: I. Suppression of ethanol consumption in laboratory rats following dopamine-beta-hydroxylase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18358987" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17920248" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10667795" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24710621" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Yohimbine administration and cue-reactivity in cocaine-dependent individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24395021" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001009" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Altered salivary alpha-amylase awakening response in Bosnian War refugees with posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10560025" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3529831" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25036580" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prazosin in the treatment of PTSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480470" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Duloxetine: a review of its use in the treatment of generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19266185" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3021083" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21342080" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : New treatment options for panic disorder: clinical trials from 2000 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829264" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of yohimbine in obsessive compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044210" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9690186" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : "Seeking safety": outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11516925" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: description of procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30211576" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : WHO World Mental Health Surveys International College Student Project: Prevalence and distribution of mental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10934574" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Psychiatric disorders among drug dependent subjects: are they primary or secondary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801724" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801724" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16893482" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Caffeine intake, toxicity and dependence and lifetime risk for psychiatric and substance use disorders: an epidemiologic and co-twin control analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6699269" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effects of caffeine on anxiety and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16639148" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The diagnosis and management of benzodiazepine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18552741" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mood disorders and substance use disorder: a complex comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222275" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The role of childhood risk factors in initiation of alcohol use and progression to alcohol dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1590549" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1356491" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : MDMA (Ecstasy) precipitation of panic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592911" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Alcohol use disorders and panic disorder: a review of the evidence of a direct relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896786" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Clinical features of cocaine-induced panic.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
